, a unit of measurement for water flow or capacity. If this is a reference to a specific technical manual or industrial model (such as a pump or water treatment component), it may be an internal company identifier. If you intended to "create text" using a specific software or tool that uses this ID, please provide a bit more context about the platform or industry. In the meantime, if you are looking for general instructions on adding text to digital assets, here are common methods: Microscope Imaging (ImageJ/FIJI)
| Species | Study | No‑Observed‑Adverse‑Effect Level (NOAEL) | Findings | |---------|-------|-------------------------------------------|----------| | | Oral (0.5‑100 mg/kg/day) | 30 mg/kg/day | No clinical signs; mild hepatocellular vacuolation at 100 mg/kg (reversible). | | Dog (90‑day) | Oral (1‑50 mg/kg/day) | 10 mg/kg/day | No mortality; transient increase in serum bilirubin at 50 mg/kg (resolved). | | Genotoxicity | Ames, Chromosome Aberration, Micronucleus | Negative across assays. | | Cardiac safety | hERG assay (IC₅₀ ≈ > 30 µM) | No QTc prolongation in telemetry‑monitored dogs (up to 20 mg/kg). | | Reproductive toxicity | Rat embryo‑fetal (GD 6‑15) | 20 mg/kg/day | No teratogenicity; slight decrease in fetal weight at highest dose (statistically non‑significant). | migd-061
| Model | Dosing Regimen | Endpoints & Results | |-------|----------------|---------------------| | | 30 mg/kg PO QD, 21 days | Tumor growth inhibition (TGI) = 62 % vs. vehicle; enhanced CD8⁺ T‑cell infiltration (↑ 2.3‑fold). | | Humanized NSG mouse xenograft (A549) + anti‑PD‑1 | MIGD‑061 15 mg/kg PO QD + pembrolizumab 10 mg/kg IP Q3D | Combination TGI = 84 % (vs. 48 % for pembrolizumab alone). | | SOD1‑G93A ALS mouse model | 10 mg/kg PO BID, started at P60 | Delayed onset of motor decline by 12 days; ↑ survival median + 8 days (p = 0.03). | | Dengue virus (DENV‑2) in AG129 mice | 25 mg/kg PO BID, 5 days post‑infection | Viral load in serum ↓ 1.7 log₁₀; survival 70 % vs. 30 % in control. | , a unit of measurement for water flow or capacity
The ISR orchestrates cellular adaptation to amino‑acid deprivation, oxidative stress, and viral infection. Hyper‑activation of GCN2 has been linked to tumor immune evasion (via PD‑L1 up‑regulation), chronic neurodegeneration, and viral replication. Consequently, selective GCN2 inhibition is being explored for oncology, neuro‑inflammation, and infectious disease. In the meantime, if you are looking for
– This review synthesises all publicly‑available information on MIGD‑061 (also referenced as “MIGD‑061”) up to April 2026, focusing on its chemical profile, mechanism of action, pre‑clinical pharmacology, early clinical data, safety signals, and market outlook. Where data are proprietary or not disclosed, the gaps are highlighted and speculative commentary is clearly flagged.
Note: All DMPK data stem from Migdra’s pre‑clinical dossier (internal slides, 2023‑2024) and have not yet been validated by third‑party CROs.
Just let me know — I’ll draft a professional, useful feature for MIGD-061 right away.